Even in patients with alterations in genes constituting the TP53/RB1 pathway, including CDKN2A/CDKN2B, tr-ALL patients had a higher mutation frequency (50%, 4/8) than dn-ALL patients (33.3%, 21/63). The gene discussed is TP53; the disease is acute lymphoblastic leukemia.